These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21681815)

  • 21. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression.
    Perahia DG; Quail D; Desaiah D; Montejo AL; Schatzberg AF
    J Psychiatr Res; 2009 Feb; 43(5):512-8. PubMed ID: 18707693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
    Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
    Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
    Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
    J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine.
    Joffe H; Soares CN; Petrillo LF; Viguera AC; Somley BL; Koch JK; Cohen LS
    J Clin Psychiatry; 2007 Jun; 68(6):943-50. PubMed ID: 17592922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
    Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
    Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
    Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
    Hong J; Novick D; Montgomery W; Moneta MV; Dueñas H; Peng X; Haro JM
    Asia Pac Psychiatry; 2016 Mar; 8(1):51-9. PubMed ID: 25808275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.
    Sheehan DV; Meyers AL; Prakash A; Robinson MJ; Swindle RW; Russell JM; Mallinckrodt CH
    Curr Med Res Opin; 2008 Sep; 24(9):2457-66. PubMed ID: 18662492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duloxetine in the long-term treatment of major depressive disorder.
    Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
    J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
    Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
    Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
    Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
    Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
    J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.
    Arnold LM; Rosen A; Pritchett YL; D'Souza DN; Goldstein DJ; Iyengar S; Wernicke JF
    Pain; 2005 Dec; 119(1-3):5-15. PubMed ID: 16298061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine.
    Marangell LB; Clauw DJ; Choy E; Wang F; Shoemaker S; Bradley L; Mease P; Wohlreich MM
    Pain; 2011 Jan; 152(1):31-37. PubMed ID: 20598442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.
    Rovera C; Mauri MC; Bertin E; Di Pace C; Paletta S; Reggiori A; De Gaspari IF; Cattaneo D; Mari D; Altamura AC
    Hum Psychopharmacol; 2016 Sep; 31(5):349-55. PubMed ID: 27400882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies.
    Mancini M; Sheehan DV; Demyttenaere K; Amore M; Deberdt W; Quail D; Sagman D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):298-309. PubMed ID: 22954893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.